Sanjivani Paranteral Past Earnings Performance
Past criteria checks 4/6
Sanjivani Paranteral has been growing earnings at an average annual rate of 57%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 19.4% per year. Sanjivani Paranteral's return on equity is 22.1%, and it has net margins of 11.3%.
Key information
57.0%
Earnings growth rate
58.8%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 19.4% |
Return on equity | 22.1% |
Net Margin | 11.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sanjivani Paranteral makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 544 | 62 | 41 | 0 |
31 Dec 23 | 497 | 59 | 49 | 0 |
30 Sep 23 | 438 | 52 | 41 | 0 |
30 Jun 23 | 382 | 43 | 35 | 0 |
31 Mar 23 | 355 | 45 | 39 | 0 |
31 Dec 22 | 326 | 49 | 35 | 0 |
30 Sep 22 | 311 | 57 | 36 | 0 |
30 Jun 22 | 324 | 60 | 31 | 0 |
31 Mar 22 | 306 | 48 | 35 | 0 |
31 Dec 21 | 326 | 48 | 32 | 0 |
30 Sep 21 | 298 | 34 | 30 | 0 |
30 Jun 21 | 283 | 25 | 26 | 0 |
31 Mar 21 | 251 | 14 | 28 | 0 |
31 Dec 20 | 217 | -2 | 27 | 0 |
30 Sep 20 | 199 | -11 | 28 | 0 |
30 Jun 20 | 175 | -17 | 27 | 0 |
31 Mar 20 | 164 | -17 | 28 | 0 |
31 Dec 19 | 179 | -12 | 30 | 0 |
30 Sep 19 | 234 | -13 | 30 | 0 |
30 Jun 19 | 233 | -23 | 28 | 0 |
31 Mar 19 | 251 | -21 | 30 | 0 |
31 Dec 18 | 238 | -216 | 28 | 0 |
30 Sep 18 | 195 | -229 | 29 | 0 |
30 Jun 18 | 187 | -462 | 29 | 0 |
31 Mar 18 | 182 | -531 | 37 | 0 |
31 Dec 17 | 209 | -438 | 35 | 0 |
30 Sep 17 | 266 | -458 | 37 | 0 |
30 Jun 17 | 281 | -233 | 28 | 0 |
31 Mar 17 | 328 | -262 | 33 | 0 |
31 Dec 16 | 322 | -233 | 32 | 0 |
30 Sep 16 | 562 | -190 | 30 | 0 |
30 Jun 16 | 812 | -159 | 27 | 0 |
31 Mar 16 | 1,156 | -146 | 31 | 0 |
31 Dec 15 | 1,474 | -22 | 57 | 0 |
30 Sep 15 | 1,460 | -24 | 58 | 0 |
30 Jun 15 | 1,394 | -31 | 33 | 0 |
31 Mar 15 | 1,330 | -24 | 30 | 0 |
31 Dec 14 | 1,369 | 5 | 73 | 0 |
30 Sep 14 | 1,470 | 17 | 74 | 0 |
30 Jun 14 | 1,596 | 20 | 75 | 0 |
31 Mar 14 | 1,589 | 16 | 77 | 0 |
31 Dec 13 | 1,544 | 34 | 94 | 0 |
30 Sep 13 | 1,526 | 26 | 93 | 0 |
Quality Earnings: 531569 has high quality earnings.
Growing Profit Margin: 531569's current net profit margins (11.3%) are lower than last year (12.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531569 has become profitable over the past 5 years, growing earnings by 57% per year.
Accelerating Growth: 531569's earnings growth over the past year (36.7%) is below its 5-year average (57% per year).
Earnings vs Industry: 531569 earnings growth over the past year (36.7%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: 531569's Return on Equity (22.1%) is considered high.